Mitral regurgitation (MR) is one of the most common valvular diseases worldwide, as it affects close to 1.7 % of the total population in the United States . Over the last decade, transcatheter edge to edge repair (TEER) has emerged as a viable treatment option for patients with severe MR. Current guidelines recommend TEER in patients with severe primary MR who are at prohibitive risk for surgery or in those with severe chronic secondary MR with symptoms unresponsive to medical therapy . With the rising prevalence in the use of TEER that now encompasses a wide spectrum of patients, we wanted to assess the performance of TEER using MitraClip in patients on home oxygen (home-O2) compared to those not on home-O2, in order to provide clarity on the outcomes of these patients' in-hospital and 30-day survival.